Advertisement
  • Loading metrics

Correction: Comparison of artemether-lumefantrine and chloroquine with and without primaquine for the treatment of Plasmodium vivax infection in Ethiopia: A randomized controlled trial

  • Tesfay Abreha,
  • Jimee Hwang,
  • Kamala Thriemer,
  • Yehualashet Tadesse,
  • Samuel Girma,
  • Zenebe Melaku,
  • Ashenafi Assef,
  • Moges Kassa,
  • Mark D. Chatfield,
  • Keren Z. Landman,
  • Stella M. Chenet,
  • Naomi W. Lucchi,
  • Venkatachalam Udhayakumar,
  • Zhiyong Zhou,
  • Ya Ping Shi,
  • S. Patrick Kachur,
  • Daddi Jima,
  • Amha Kebede,
  • Hiwot Solomon,
  • Addis Mekasha,
  • Bereket Hailegiorgis Alemayehu,
  • Joseph L. Malone,
  • Gunewardena Dissanayake,
  • Hiwot Teka,
  • Sarah Auburn,
  • Lorenz von Seidlein,
  •  [ ... ],
  • Ric N. Price
  • [ view all ]
  • [ view less ]

Correction: Comparison of artemether-lumefantrine and chloroquine with and without primaquine for the treatment of Plasmodium vivax infection in Ethiopia: A randomized controlled trial

  • Tesfay Abreha, 
  • Jimee Hwang, 
  • Kamala Thriemer, 
  • Yehualashet Tadesse, 
  • Samuel Girma, 
  • Zenebe Melaku, 
  • Ashenafi Assef, 
  • Moges Kassa, 
  • Mark D. Chatfield, 
  • Keren Z. Landman
PLOS
x
  • Article
  • Metrics
  • Comments
  • Media Coverage

The numbers in the second paragraph in the section entitled, “Partial primaquine dose and unsupervised primaquine treatment” are incorrect owing to a transcription error in the final preparation of the paper.

The paragraph should read: “For all subsequent recurrences, only the first dose of the antimalarial drugs was supervised. The risk of recurrence after 6 mo of follow-up between the primary and secondary treatments did not differ significantly for patients in either the CQ arm (HR = 1.2 [95% CI 0.8–1.84], p = 0.5) or the AL arm (HR = 0.8 [95% CI 0.5–1.3], p = 0.4). However, patients were at significantly greater risk of recurrent P. vivax after the unsupervised PQ retreatment than after the partially supervised initial PQ treatment: 36.8% (95%CI 16.6%–68.3%) versus 14.7% (95% CI 8.6%–24.6%) in patients in the CQ+PQ arm (HR = 3.9 [95% CI 1.3–11.4], p = 0.014) and 48.1% (95%CI 26.5%–75.6%) versus 17.5% (95%CI 10.7%–27.8%) in patients in the AL+PQ arm (HR = 3.5 [95% CI 1.4–8.9], p = 0.008) (S2 Fig).”

Reference

  1. 1. Abreha T, Hwang J, Thriemer K, Tadesse Y, Girma S, Melaku Z, et al. (2017) Comparison of artemether-lumefantrine and chloroquine with and without primaquine for the treatment of Plasmodium vivax infection in Ethiopia: A randomized controlled trial. PLoS Med 14(5): e1002299. https://doi.org/10.1371/journal.pmed.1002299 pmid:28510573